Analysed BIONEXUS GENE LAB CORP (BGLC:NASDAQ) News Sources
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
12-11-2025
yahoo.com
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
01-12-2025
yahoo.com
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
28-01-2026
yahoo.com
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
23-02-2026
yahoo.com
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
11-03-2026
yahoo.com
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
29-05-2026
yahoo.com
What is the current price of BIONEXUS GENE LAB CORP (BGLC:NASDAQ)?
The current price of BIONEXUS GENE LAB CORP (BGLC:NASDAQ) is $1.55.
BIONEXUS GENE LAB CORP (BGLC:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIONEXUS GENE LAB CORP (BGLC:NASDAQ) since the previous trading day is $-0.04.
BIONEXUS GENE LAB CORP (BGLC:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIONEXUS GENE LAB CORP (BGLC:NASDAQ) since the previous trading day is -2.5157%.
What is the most recent average sentiment score for BIONEXUS GENE LAB CORP (BGLC:NASDAQ)?
The most recent average sentiment score for BIONEXUS GENE LAB CORP (BGLC:NASDAQ) is 63 out of 100.
What is the most recent average sentiment for BIONEXUS GENE LAB CORP (BGLC:NASDAQ)?
The most recent sentiment for BIONEXUS GENE LAB CORP (BGLC:NASDAQ) is .
SEC-8K** Filing Available For BIONEXUS GENE LAB CORP (BGLC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.